BioMedNewsBreaks

MondayOct 27, 2025 12:01 pm

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Founder Gareth Sheridan Returns as CEO to Lead Final Development Phase of AVERSA Fentanyl 

Nutriband (NASDAQ: NTRB) today announced that company founder Gareth Sheridan has resumed his role as CEO, effective immediately, following a temporary period during which Co-Founder and Chairman Serguei Melnik served in the position. Sheridan will lead the company through its final 2025 development framework toward an expected 2026 NDA filing for AVERSA Fentanyl, the company’s flagship abuse-deterrent opioid patch. AVERSA Fentanyl is designed to deter misuse and accidental exposure, with potential peak annual U.S. sales estimated between $80 million and $200 million. The AVERSA(TM) technology is protected by patents in 46 countries, including the United States, Europe, and Japan. To…

Continue Reading

FridayOct 24, 2025 11:51 am

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Featured in Channelchek Report Highlighting AVERSA Fentanyl Progress

Nutriband (NASDAQ: NTRB), a pharmaceutical company developing transdermal drug delivery technologies, was featured in a Channelchek report by Noble Capital Markets summarizing its presentation at Noble’s Virtual Emerging Growth Conference. The Oct. 23, 2025, report highlights the company’s lead product, AVERSA Fentanyl, an abuse-deterrent transdermal patch that releases aversive agents if tampered with, reducing the risk of opioid misuse. Market projections estimate annual sales of $200 million, potentially rising to $800 million if the FDA mandates abuse-deterrent patches across the category. Following completion of its manufacturing scale-up with Kindeva Drug Delivery, Nutriband expects to begin a human abuse liability study…

Continue Reading

FridayOct 24, 2025 11:40 am

BioMedNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Featured in NetworkNewsWire Editorial on AI-Driven Breast Cancer Imaging

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) announced its inclusion in a NetworkNewsWire (“NNW”) editorial titled “Investors Turn to AI-Driven Imaging Firms Targeting High-Growth Breast Cancer Market.” The publication explores how artificial intelligence (AI) is reshaping medical imaging, particularly in breast cancer detection, where early and precise diagnosis remains critical to survival rates. Izotropic is highlighted for its IzoView Breast CT Imaging System, a 3D imaging technology designed to improve detection accuracy in women with dense breast tissue. The company’s innovation aligns with rising global demand for advanced diagnostic solutions, as breast cancer remains the most frequently diagnosed cancer among women…

Continue Reading

FridayOct 24, 2025 9:30 am

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Present at ThinkEquity Conference on Oct. 30

Lantern Pharma (NASDAQ: LTRN), an artificial intelligence (AI) company focused on developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery, announced that its management team will present at the ThinkEquity Conference on Thursday, Oct. 30, 2025, at 11:30 a.m. ET at the Mandarin Oriental in New York. To view the full press release, visit https://ibn.fm/XaX09 About Lantern Pharma Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR(R), leverages over 200 billion oncology-focused data points and…

Continue Reading

FridayOct 24, 2025 9:20 am

BioMedNewsBreaks – HealthLynked Corp. (OTCQB: HLYK) Launches Upgraded MedOfficeDirect Platform on Shopify

HealthLynked (OTCQB: HLYK), a leading provider of healthcare technology and patient engagement solutions, announced the launch of its new MedOfficeDirect e-commerce platform, now live at DiscountOnlineMedicalSupplies.com and built on Shopify. The upgraded platform delivers faster performance, enhanced security, and a modern checkout experience while offering an average 20% price reduction across its catalog of brand-name medical supplies. HealthLynked plans to expand the curated inventory and, upon completing its marketing and backend transition, migrate the platform back to MedOfficeDirect.com. CEO Dr. Michael Dent said the launch represents a major step forward in accessibility and scalability, enabling patients and healthcare providers to…

Continue Reading

ThursdayOct 23, 2025 12:57 pm

BioMedNewsBreaks — Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) CEO Discusses IzoView Commercialization Strategy in New Departures Capital Interview 

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company developing advanced imaging technologies for the detection and treatment of breast cancer, announced the release of a new video interview with CEO Bob Thast in partnership with Departures Capital. The discussion highlights Izotropic’s vision and near-term strategy for its flagship IzoView breast CT platform, detailing its imaging advantages, patient benefits, and market differentiation. Thast also outlines plans for capital deployment over the next 12–18 months, including production of three IzoView units for an upcoming U.S. FDA clinical study, a partner device in the U.K. to support CE-mark activities, and…

Continue Reading

ThursdayOct 23, 2025 11:35 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Announces Three Accepted Abstracts on Deciparticle (TM) Everolimus (Sapu003) at 2025 San Antonio Breast Cancer Symposium

Oncotelic Therapeutics (OTCQB: OTLC), a biopharmaceutical company developing transformative cancer therapies through its PDAOAI platform and expertise in nanomedicines, announced that three abstracts featuring its investigational intravenous Deciparticle (TM) everolimus (Sapu003) have been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium, to be held Dec. 9–12 in San Antonio, Texas. Developed by Sapu Nano—a joint venture between Oncotelic and Dragon Oversea—Sapu003 is a novel IV formulation of everolimus designed to overcome the limitations of oral mTOR inhibitors such as Afinitor (R), including poor bioavailability and restricted tumor penetration. The abstracts collectively detail the clinical rationale, molecular biomarkers,…

Continue Reading

WednesdayOct 22, 2025 2:03 pm

BioMedNewsBreaks — Branded Legacy, Inc. (OTC: BLEG) Advances FDA Pathway for Intranasal Naloxone with Pre-ANDA Briefing Preparation

Branded Legacy (OTC: BLEG), a holding company focused on life sciences and wellness innovation, announced that its subsidiary, BioLegacy Evaluative Group, has begun preparing its FDA Pre-Abbreviated New Drug Application (Pre-ANDA) briefing package for a proprietary intranasal naloxone spray. The milestone follows BioLegacy’s provisional patent filing for its air-driven delivery platform, designed to offer a cost-effective, scalable solution to the opioid overdose crisis. The submission includes a Target Product Profile for 2 mg and 4 mg naloxone HCl nasal sprays, Chemistry, Manufacturing and Controls specifications, a 60-subject bioequivalence study against Narcan(R), and human factors testing to ensure accessibility for non-medical users.…

Continue Reading

WednesdayOct 22, 2025 11:14 am

BioMedNewsBreaks — Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Featured in NetworkNewsWire Editorial on AI-Driven 3D Imaging for Breast Cancer Detection

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), developer of the IzoView Breast CT Imaging System, announces its inclusion in a NetworkNewsWire (“NNW”) editorial titled “Investors Eye Next-Gen 3D AI-Imaging Technologies in Growing $9 Billion Market.” The piece highlights how artificial intelligence is transforming medical imaging, particularly in breast cancer diagnostics, where early and accurate detection remains critical. Izotropic’s dedicated 3D imaging platform is designed to enhance detection precision, especially for women with dense breast tissue, positioning the company at the forefront of innovation in a rapidly expanding global market. To view the full press release, visit https://ibn.fm/saP3D About Izotropic Corporation Izotropic…

Continue Reading

WednesdayOct 22, 2025 9:15 am

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Advances HyBryte(TM) as Potential First-Line CTCL Treatment with Promising FLASH Results 

Soligenix (NASDAQ: SNGX) is continuing to build momentum in the treatment of early-stage cutaneous T-cell lymphoma (“CTCL”) through promising results from its pivotal FLASH trial and ongoing FLASH 2 confirmatory study. HyBryte(TM)—a novel, non-UV light-activated therapy using synthetic hypericin—has demonstrated statistically significant efficacy and safety, offering hope in a field where therapeutic innovation has lagged. In the original FLASH study, nearly half of patients showed meaningful response at 18 weeks, and interim results from an independent University of Pennsylvania study reported a 75% response rate. FLASH 2 builds on these findings with improved design while addressing regulatory requirements for confirmatory…

Continue Reading